BIONOMOUS RAISES CHF 1.3 MILLION SEED FUNDING IN A ROUND LED BY NIVALIS GROUP

PRESS RELEASE

Villaz-St-Pierre, 9 September 2021


BIONOMOUS, the Swiss-based startup who builds devices to automate processes in Life Science research, announces today it has raised a CHF 1.3 million Seed funding round led by Nivalis Group, with participation from SICTIC business angels and Venture Kick. 

Experts in mechatronics, microfluidics and machine learning, Bionomous develops the EggSorter, a device that automatically inspects, sorts and dispenses small biological entities like the eggs of zebrafish, a small freshwater fish native to South Asia. Its eggs are particularly suited for research in the Life Sciences industry, to find new treatments, perform toxicology tests or better understand the biology and genetics of living organisms.

The investment from Nivalis Group marks the start of a new development phase for Bionomous.

PRESS RELEASE Bionomous raises CHF 1.3 million Seed funding in a round led by Nivalis Group

Nivalis Group CEO Nicolas Corsi

Nivalis Group CEO Nicolas Corsi

“We are confident that Bionomous is a great addition to the Nivalis Group family. With this investment we ticked off all the boxes we look for in a startup: a growing market segment, a product with excellent traction, a great team, and several underlying technologies that match our existing investments and allow us to create interesting synergies.”

Bionomous co-founders Ana Hernando and Frank Bonnet

Bionomous CEO and co-founder Frank Bonnet

“Our team has demonstrated its capacity to develop products tailored to the specific needs of our customers. This new investment, in addition to the interest of early adopters and the first confirmed orders we received despite the COVID pandemic, allow us to confidently move to the next development phase of our final product and to target a commercialization over the next two years.”


Bionomous CMO and co-founder Ana Hernando

“Leaders in the zebrafish field have expressed great interest in the EggSorter, which gives us the confidence to launch it to the market. Furthermore, we have received several requests to use our technology in other fields such as personalized medicine, diagnostics and aquaculture. Thanks to this investment round, our team can explore the possibilities to apply our technology to other segments and study new opportunities to diversify our product lines.”